A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring [electronic resource]
Producer: 20200619Description: 2699-2707 p. digitalISSN:- 1557-3265
- Adult
- Aged
- Benzimidazoles -- pharmacokinetics
- Drug Administration Schedule
- Female
- Follow-Up Studies
- Gene Fusion
- Humans
- Male
- Maximum Tolerated Dose
- Middle Aged
- Mutation
- Neoplasms -- drug therapy
- Prognosis
- Protein Kinase Inhibitors -- pharmacokinetics
- Pyrazoles -- pharmacokinetics
- Receptor, Fibroblast Growth Factor, Type 1 -- antagonists & inhibitors
- Receptor, Fibroblast Growth Factor, Type 2 -- antagonists & inhibitors
- Receptor, Fibroblast Growth Factor, Type 3 -- antagonists & inhibitors
- Signal Transduction
- Tissue Distribution
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.